Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Virginia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Virginia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Virginia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Yuvraj Choudhary (NPI 1396988747)

Field	Value
Entity Type	Individual
Organization	Yuvraj Choudhary
Address	1401 Johnston Willis Dr Ste 100
City	North Chesterfield
State	VA
ZIP	23235
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 15, 2009

Payer Source	Total Paid
Medicare	$2.3M
Medicaid	$0

Key Findings

This provider is effectively single‑payer on file: lifetime Medicare revenue is $2.3M while Medicaid billing is listed as none, indicating no Medicaid activity in the dataset and heavy reliance on Medicare as the primary public payer. That concentration in a single federal payer should be considered when assessing revenue risk and contracting opportunities.

Revenue is highly concentrated in three drug administration codes: J9271 ($756.8K, 33.4%), J9299 ($556.6K, 24.5%), and J9144 ($307.8K, 13.6%), which together account for 71.5% of this provider's Medicare revenue. This top‑three concentration underscores that a small set of high‑cost biologic administrations drives the majority of billed Medicare dollars.

The code mix is consistent with a hematology/oncology infusion practice that emphasizes immune checkpoint inhibitors and monoclonal antibodies: J9271 (pembrolizumab), J9299 (nivolumab) and J9144 (daratumumab) are the leading revenue generators, supported by chemotherapy administration codes such as 96413 and infusion continuity codes like 96417 and G0498. Presence of supportive drug codes (e.g., pegfilgrastim Q5108/J2506 and immune globulin J1569) further indicates longitudinal oncology care with on‑site infusion and supportive treatment services.

Competitive standing on the top biologics is modest-to-typical nationally: J9271 ranks #522 of 1841 (71th percentile, described as typical), J9299 ranks #112 of 505 (78th percentile, typical) and J9144 ranks #308 of 615 (49th percentile, typical). These rankings indicate the provider has meaningful but not dominant national volume for these agents and operates at a level comparable to many peers rather than as a high‑volume national center.

Office/clinic evaluation-and-management volume is an outlier relative to national peers: 99214 shows 1.3K claims and $127.3K revenue (5.6%) and is labeled an extreme outlier (rank #5315 of 479517, 99th percentile), while 99213 (934 claims, $59.8K, 2.6%) is also an extreme outlier (rank #7596 of 457151, 98th percentile). This suggests unusually high ambulatory visit throughput for established patients, consistent with frequent follow‑up or ongoing management visits for patients receiving serial infusions.

Several diagnostic and procedure codes are also above typical volumes, supporting the hematology focus: bone marrow biopsy 38222 (74 claims, $10.1K, 0.4%) ranks #120 of 3230 (96th percentile, notably above typical), and flow cytometry add‑on 88185 (1.9K claims, $30.8K, 1.4%) ranks #137 of 618 (78th percentile, typical). These findings indicate the practice performs on‑site diagnostic workups in addition to therapeutic infusions, reinforcing a comprehensive hematology/oncology service line.

Use of supportive care agents is evident and contributes meaningfully to revenue: immune globulin J1569 accounts for $124.6K (5.5%) and ranks #269 of 542 (50th percentile), while pegfilgrastim biosimilars Q5108 and originator J2506 appear among top codes. This pattern aligns with routine management of treatment‑related cytopenias and infection prophylaxis in an oncology population receiving repeated biologic or cytotoxic therapies.

The provider has an established billing history (NPI enumerated 2009-04-15, ~17 years ago), and the combination of $2.3M in Medicare revenue, concentrated biologic infusions, high E/M visit counts, and on‑site diagnostics paints the picture of a mature, clinic‑based hematology/oncology practice with sustained Medicare activity rather than a new or transient billing profile.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

53 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	17,600	$40	$756.8K
J9299	Injection, nivolumab, 1 mg	24,200	$20	$556.6K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	8,100	$40	$307.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,330	$100	$127.3K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	3,560	$40	$124.6K
J0897	Injection, denosumab, 1 mg	4,080	$20	$73.4K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	930	$60	$59.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	490	$100	$48.7K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	350	$90	$32K
88185	The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with…	1,920	$20	$30.8K

Showing 1–10 of 53

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 53 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Virginia Distribution

Yuvraj Choudhary — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Virginia

Full comparison — all codes billed, vs. state median

53 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	25	110	12,800	$40	$610.9K
J9299	3	30	12,920	$20	$335.4K
J9144	29	60	8,280	$40	$332.7K
J1569	10	30	3,000	$40	$135.7K
J0897	123	340	2,820	$20	$89.3K
88185	7	60	620	$20	$34.3K
J2506	20	40	360	$80	$31.2K
Q5108	6	20	320	$90	$30.3K
96413	31	230	250	$100	$28.5K
99214	176	12,890	140	$80	$21K

Showing 1–10 of 53

Related Providers

Other providers that share a Tax Identification Number (TIN) with Yuvraj Choudhary, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Maura Hagan	VA	Hematology & Oncology Physician	$1.9M	$0
Pablo Gonzalez	VA	Hematology & Oncology Physician	$1.5M	$0
Joshua Mcfarlane	VA	Hematology & Oncology Physician	$1.5M	$0
Elke Friedman	FL	Medical Oncology Physician	$1.3M	$0
Purvi Shah	VA	Hospice and Palliative Medicine (Internal Medicine) Physician	$1.3M	$0
Angela Vanlandingham	VA	Hematology & Oncology Physician	$1.2M	$0
Thomas Weart	VA	Hematology & Oncology Physician	$1.1M	$0
Will Voelzke	VA	Hematology & Oncology Physician	$1.1M	$0
James Khatcheressian	VA	Hematology & Oncology Physician	$1.1M	$0
Reed Mitchell	VA	Hematology & Oncology Physician	$1M	$0

Nearby Providers

Other providers in the same ZIP code as Yuvraj Choudhary, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lighthouse Behavioral Health Center, LLC	VA	Community/Behavioral Health Agency	$0	$16.5M
Radiology Associates Of Richmond Inc	VA	Diagnostic Radiology Physician	$0	$14.2M
Hobby Home Care, LLC	VA	Home Health Agency	$0	$12M
The Pediatric Connection, Inc	VA	Nursing Care Agency	$0	$11.7M
Caremed, Inc	VA	Home Health Agency	$0	$10.7M
Care Advantage, Inc	VA	Home Health Agency	$0	$10.7M
Family Guidance Of Virginia	VA	Community/Behavioral Health Agency	$0	$9.6M
Daily Grace, LLC	VA	Community/Behavioral Health Agency	$0	$9.1M
Trinity Care LLC	VA	Community/Behavioral Health Agency	$0	$7.8M
Stony Point Surgery Center, L.L.C	VA	Ambulatory Surgical Clinic/Center	$4.9M	$1.4M

Yuvraj Choudhary — Billing Profile & Reimbursement Data

Sign up for Yuvraj Choudhary — Billing Profile & Reimbursement Data policy alerts

Yuvraj Choudhary — Billing Profile & Reimbursement Data

Sign up for Yuvraj Choudhary — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References